Sara K Vesely

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8831456/publications.pdf

Version: 2024-02-01

192 11,533 55 102 papers citations h-index g-index

192 192 192 192 7853

times ranked

citing authors

docs citations

all docs

#	Article	IF	CITATIONS
1	Antithrombotic Therapy in Neonates and Children. Chest, 2012, 141, e737S-e801S.	0.8	1,229
2	American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Advances, 2019, 3, 3829-3866.	5. 2	684
3	ADAMTS13 activity in thrombotic thrombocytopenic purpuraâ€"hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood, 2003, 102, 60-68.	1.4	649
4	Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood, 2004, 104, 2623-2634.	1.4	561
5	Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood, 2010, 115, 1500-1511.	1.4	477
6	The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports. American Journal of Hematology, 2010, 85, 174-180.	4.1	308
7	Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood, 2015, 125, 616-618.	1.4	282
8	American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism. Blood Advances, 2018, 2, 3292-3316.	5.2	273
9	Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma. Transfusion, 2004, 44, 294-304.	1.6	219
10	Parental communication and youth sexual behaviour. Journal of Adolescence, 2007, 30, 449-466.	2.4	210
11	Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015. Blood Advances, 2017, 1, 590-600.	5 . 2	207
12	Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: Comparison of incidence, demographic and clinical features. Pediatric Blood and Cancer, 2013, 60, 1676-1682.	1.5	193
13	ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2020, 18, 2496-2502.	3 . 8	188
14	Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura. Blood, 2008, 112, 4003-4008.	1.4	171
15	Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. Blood, 2013, 122, 2023-2029.	1.4	161
16	ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2020, 18, 2486-2495.	3.8	142
17	Quinine-Associated Thrombotic Thrombocytopenic Purpura–Hemolytic Uremic Syndrome: Frequency, Clinical Features, and Long-Term Outcomes. Annals of Internal Medicine, 2001, 135, 1047.	3.9	139
18	Complications of plasma exchange in patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion, 2006, 46, 154-156.	1.6	131

#	Article	IF	Citations
19	Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. Blood, 2010, 116, 2127-2133.	1.4	127
20	The Oklahoma thrombotic thrombocytopenic Purpura-Hemolytic uremic syndrome (TTP-HUS) registry: a community perspective of patients with clinically diagnosed TTP-HUS. Seminars in Hematology, 2004, 41, 60-67.	3.4	125
21	Pregnancy outcomes after recovery from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion, 2004, 44, 1149-1158.	1.6	124
22	The Potential Protective Effect of Youth Assets on Adolescent Alcohol and Drug Use. American Journal of Public Health, 2004, 94, 1425-1430.	2.7	118
23	Disseminated Malignancy Misdiagnosed as Thrombotic Thrombocytopenic Purpura: A Report of 10 Patients and a Systematic Review of Published Cases. Oncologist, 2007, 12, 11-19.	3.7	117
24	Management of Adult Patients with Persistent Idiopathic Thrombocytopenic Purpura Following Splenectomy. Annals of Internal Medicine, 2004, 140, 112.	3.9	114
25	The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura. Blood, 2015, 125, 1526-1531.	1.4	102
26	Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura. Transfusion, 2009, 49, 873-887.	1.6	99
27	Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura. Blood, 2016, 127, 3092-3094.	1.4	99
28	The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings at enrollment until 2017. Haematologica, 2019, 104, 2107-2115.	3 . 5	99
29	Reliability and validity of the youth asset survey (YAS). Journal of Adolescent Health, 2002, 31, 247-255.	2.5	98
30	Rituximab therapy for thrombotic thrombocytopenic purpura: A proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders. Journal of Clinical Apheresis, 2006, 21, 49-56.	1.3	97
31	<scp>D</scp> rugâ€induced thrombotic microangiopathy: <scp>E</scp> xperience of the <scp>O</scp> klahoma registry and the BloodCenter of <scp>W</scp> isconsin. American Journal of Hematology, 2015, 90, 406-410.	4.1	95
32	Ferriman Gallwey Self-Scoring I: Performance Assessment in Women with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4112-4114.	3.6	92
33	The potential protective effects of youth assets from adolescent sexual risk behaviors. Journal of Adolescent Health, 2004, 34, 356-365.	2.5	88
34	Systemic infections mimicking thrombotic thrombocytopenic purpura. American Journal of Hematology, 2011, 86, 743-751.	4.1	87
35	Bleeding manifestations and management of children with persistent and chronic immune thrombocytopenia: data from the Intercontinental Cooperative ITP Study Group (ICIS). Blood, 2013, 121, 4457-4462.	1.4	87
36	Adolescent Violence: The Protective Effects of Youth Assets. Journal of Counseling and Development, 2004, 82, 268-276.	2.4	81

3

#	Article	IF	CITATIONS
37	Clinical cardiac involvement in thrombotic thrombocytopenic purpura: a systematic review. Transfusion, 2008, 48, 382-392.	1.6	76
38	Severe deficiency of VWF-cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients. Transfusion, 2004, 44, 146-150.	1.6	75
39	Pancreatitis preceding acute episodes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: report of five patients with a systematic review of published reports. Haematologica, 2007, 92, 936-943.	3.5	75
40	Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolyticâ€uremic syndromes. American Journal of Hematology, 2010, 85, 844-847.	4.1	75
41	Prevalence of primary immune thrombocytopenia in Oklahoma. American Journal of Hematology, 2012, 87, 848-852.	4.1	75
42	Adolescent Tobacco Use: The Protective Effects of Developmental Assets. American Journal of Health Promotion, 2002, 16, 198-205.	1.7	74
43	Fatigue in adult patients with primary immune thrombocytopenia. European Journal of Haematology, 2011, 86, 420-429.	2.2	74
44	Cognitive deficits after recovery from thrombotic thrombocytopenic purpura. Transfusion, 2009, 49, 1092-1101.	1.6	73
45	Complications of plasma exchange in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: a study of 78 additional patients. Transfusion, 2003, 43, 415-416.	1.6	69
46	Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura. Haematologica, 2012, 97, 297-303.	3.5	69
47	Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura. Blood, 2016, 128, 2175-2178.	1.4	68
48	Initial management of immune thrombocytopenic purpura in adults: A randomized controlled trial comparing intermittent anti-D with routine care. American Journal of Hematology, 2003, 74, 161-169.	4.1	64
49	Corticosteroid sideâ€effects and risk for bleeding in immune thrombocytopenic purpura: patient and hematologist perspectives. European Journal of Haematology, 2009, 83, 175-182.	2.2	64
50	Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpuraâ€hemolytic uremic syndrome, 1996 to 2011 (CME). Transfusion, 2012, 52, 2525-2532.	1.6	63
51	Longâ€ŧerm deficits in healthâ€related quality of life after recovery from thrombotic thrombocytopenic purpura. Transfusion, 2009, 49, 118-124.	1.6	61
52	Pregnancy outcomes following recovery from acquired thrombotic thrombocytopenic purpura. Blood, 2014, 123, 1674-1680.	1.4	61
53	Factor V Leiden: a genetic risk factor for thrombotic microangiopathy in patients with normal von Willebrand factor–cleaving protease activity. Blood, 2002, 99, 437-442.	1.4	60
54	Depression and cognitive impairment following recovery from thrombotic thrombocytopenic purpura. American Journal of Hematology, 2015, 90, 709-714.	4.1	59

#	Article	IF	Citations
55	Relationships Among Youth Assets and Neighborhood and Community Resources. Health Education and Behavior, 2005, 32, 380-397.	2.5	58
56	An Adolescent Age Group Approach to Examining Youth Risk Behaviors. American Journal of Health Promotion, 2002, 16, 167-176.	1.7	56
57	Surgery Versus Surveillance for Well-Differentiated, Nonfunctional Pancreatic Neuroendocrine Tumors: An 11-Year Analysis of the National Cancer Database. Oncologist, 2020, 25, e276-e283.	3.7	55
58	Protective Assets for Non-use of Alcohol, Tobacco and Other Drugs among Urban American Indian Youth in Oklahoma. Maternal and Child Health Journal, 2008, 12, 82-90.	1.5	54
59	Self-Reported Initial Management of Childhood Idiopathic Thrombocytopenic Purpura: Results of a Survey of Members of the American Society of Pediatric Hematology/Oncology, 2001. Journal of Pediatric Hematology/Oncology, 2003, 25, 130-133.	0.6	52
60	Predictors of remission in children with newly diagnosed immune thrombocytopenia: Data from the Intercontinental Cooperative ITP Study Group Registry II participants. Pediatric Blood and Cancer, 2018, 65, e26736.	1.5	51
61	Sporadic bloody diarrhoeaâ€associated thrombotic thrombocytopenic purpuraâ€haemolytic uraemic syndrome: an adult and paediatric comparison. British Journal of Haematology, 2008, 141, 696-707.	2.5	50
62	The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis. Blood Coagulation and Fibrinolysis, 2016, 27, 648-652.	1.0	49
63	Frequency and Significance of HIV Infection among Patients Diagnosed with Thrombotic Thrombocytopenic Purpura. Clinical Infectious Diseases, 2009, 48, 1129-1137.	5.8	48
64	The Association between Multiple Youth Assets and Sexual Behavior. American Journal of Health Promotion, 2004, 19, 12-18.	1.7	47
65	Self-Reported Diagnostic and Management Strategies in Childhood Idiopathic Thrombocytopenic Purpura: Results of a Survey of Practicing Pediatric Hematology/Oncology Specialists. The American Journal of Pediatric Hematology/oncology, 2000, 22, 55-61.	1.3	47
66	A Longitudinal Study of Youth Assets, Neighborhood Conditions, and Youth Sexual Behaviors. Journal of Adolescent Health, 2013, 52, 779-785.	2.5	44
67	Diversity and severity of adverse reactions to quinine: A systematic review. American Journal of Hematology, 2016, 91, 461-466.	4.1	43
68	Youth Assets and Sexual Risk Behavior: The Importance of Assets for Youth Residing in One-Parent Households. Perspectives on Sexual and Reproductive Health, 2005, 37, 25-31.	3.3	43
69	Complications of plasma exchange in patients treated for thrombotic thrombocytopenic purpura. IV. An additional study of 43 consecutive patients, 2005 to 2008. Transfusion, 2009, 49, 392-394.	1.6	42
70	Overlapping Features of Thrombotic Thrombocytopenic Purpura and Systemic Lupus Erythematosus. Southern Medical Journal, 2007, 100, 512-514.	0.7	40
71	The Oklahoma Thrombotic Thrombocytopenic Purpura–Hemolytic Uremic Syndrome Registry: the Swiss connection. European Journal of Haematology, 2008, 80, 277-286.	2.2	40
72	Twiceâ€daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, 1989 through 2006. Transfusion, 2008, 48, 349-357.	1.6	38

#	Article	IF	CITATIONS
73	Lessons learned from the Oklahoma Thrombotic Thrombocytopenic Purpuraâ€Hemolytic Uremic Syndrome Registry. Journal of Clinical Apheresis, 2008, 23, 129-137.	1.3	38
74	Clinical Utility of D-dimer in Patients With Suspected Pulmonary Embolism and Nondiagnostic Lung Scans or Negative CT Findings. Chest, 2004, 125, 851-855.	0.8	37
75	Schoolâ€Related Assets and Youth Risk Behaviors: Alcohol Consumption and Sexual Activity. Journal of School Health, 2012, 82, 3-10.	1.6	37
76	Reliability and Validity of the Youth Asset Survey: An Update. American Journal of Health Promotion, 2010, 25, e13-e24.	1.7	36
77	Hormonal Contraception and Risk of Thromboembolism in Women With Diabetes. Diabetes Care, 2017, 40, 233-238.	8.6	36
78	Thrombotic microangiopathic syndromes associated with drugs, HIV infection, hematopoietic stem cell transplantation and cancer. Presse Medicale, 2012, 41, e177-e188.	1.9	35
79	Youth Assets and Sexual Risk Behavior: Differences Between Male and Female Adolescents. Health Education and Behavior, 2010, 37, 343-356.	2.5	33
80	Quinine-Induced Thrombotic Microangiopathy: A Report ofÂ19ÂPatients. American Journal of Kidney Diseases, 2017, 70, 686-695.	1.9	30
81	Mobile Application vs Paper Pictorial Blood Assessment Chart to Track Menses in Young Women: A Randomized Cross-over Design. Journal of Pediatric and Adolescent Gynecology, 2018, 31, 84-88.	0.7	29
82	A support group for patients who have recovered from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS): The six-year experience of the Oklahoma TTP-HUS Study Group. Journal of Clinical Apheresis, 2003, 18, 16-20.	1.3	28
83	Youth-parent communication and youth sexual behavior: implications for physicians. Family Medicine, 2006, 38, 500-4.	0.5	28
84	Unintentional platelet removal by plasmapheresis. Journal of Clinical Apheresis, 2001, 16, 55-60.	1.3	27
85	Methodological Considerations in a Community-Based Longitudinal Study. American Journal of Health Behavior, 2009, 33, 58-68.	1.4	27
86	Blood group O and black race are independent risk factors for thrombotic thrombocytopenic purpura associated with severe ADAMTS13 deficiency. Transfusion, 2011, 51, 2237-2243.	1.6	27
87	The Predictive Influence of Family and Neighborhood Assets on Fighting and Weapon Carrying from Mid- to Late Adolescence. Prevention Science, 2014, 15, 473-484.	2.6	26
88	Conflicts of Interest and Clinical Recommendations. American Journal of Medical Quality, 2014, 29, 53-60.	0.5	26
89	Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences. Blood Advances, 2020, 4, 2351-2365.	5.2	26
90	Does Family Structure Matter in the Relationships Between Youth Assets and Youth Alcohol, Drug and Tobacco Use?. Journal of Research on Adolescence, 2007, 17, 743-766.	3.7	25

#	Article	IF	Citations
91	Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2020, 18, 2503-2512.	3.8	25
92	First symptoms in patients with thrombotic thrombocytopenic purpura: what are they and when do they occur?. Transfusion, 2013, 53, 235-237.	1.6	24
93	Youth Assets, Aggression, and Delinquency Within the Context of Family Structure. American Journal of Health Behavior, 2005, 29, 557-568.	1.4	21
94	Drug-induced thrombocytopenia in children. Pediatric Blood and Cancer, 2013, 60, 1975-1981.	1.5	21
95	GRADE notes: How to use GRADE when there is "no―evidence? A case study of the expert evidence approach. Journal of Clinical Epidemiology, 2021, 137, 231-235.	5.0	21
96	Drug-Induced Thrombocytopenia. Drug Safety, 2009, 32, 85-86.	3.2	20
97	Prospective Associations Among Youth Assets in Young Adults and Tobacco Use. American Journal of Preventive Medicine, 2015, 48, S94-S101.	3.0	20
98	Diagnosis of thrombotic thrombocytopenic purpura among patients with ADAMTS13 Activity 10%â€20%. American Journal of Hematology, 2017, 92, E644-E646.	4.1	20
99	Pulmonary involvement in patients with thrombotic thrombocytopenic purpura. European Journal of Haematology, 2014, 92, 156-163.	2.2	18
100	Rituximab for thrombotic thrombocytopenic purpura: lessons from the STAR trial. Transfusion, 2017, 57, 2532-2538.	1.6	18
101	Immune Thrombocytopenic Purpura — Let the Treatment Fit the Patient. New England Journal of Medicine, 2003, 349, 903-905.	27.0	17
102	Quinine Allergy Causing Acute Severe Systemic Illness: Report of 4 Patients Manifesting Multiple Hematologic, Renal, and Hepatic Abnormalities. Baylor University Medical Center Proceedings, 2003, 16, 21-26.	0.5	16
103	Plasma exchange complications in patients treated for thrombotic thrombocytopenia purpura-hemolytic uremic syndrome: 2011 to 2014. Transfusion, 2014, 54, 3257-3259.	1.6	16
104	An Open-Label, Single-Arm, Efficacy Study of Tranexamic Acid in Adolescents with Heavy Menstrual Bleeding. Journal of Pediatric and Adolescent Gynecology, 2019, 32, 305-311.	0.7	16
105	Thrombotic Thrombocytopenic Purpura: From the Bench to the Bedside, but Not Yet to the Community. Annals of Internal Medicine, 2003, 138, 152.	3.9	15
106	Adjuvant chemotherapy for the "oldest old―ovarian cancer patients. Cancer, 2009, 115, 1472-1480.	4.1	15
107	Determinants of Salivary Cotinine Concentrations Among Smokeless Tobacco Users. Nicotine and Tobacco Research, 2012, 14, 1229-1234.	2.6	15
108	Central nervous system metastasis in gynecologic cancer: Symptom management, prognosis and palliative management strategies. Gynecologic Oncology, 2015, 136, 472-477.	1.4	15

#	Article	lF	CITATIONS
109	Youth Assets and Delayed Coitarche Across Developmental Age Groups. Journal of Early Adolescence, 2010, 30, 277-304.	1.9	14
110	Increased Urinary Albumin Excretion Following Recovery From Thrombotic Thrombocytopenic Purpura Due to Acquired ADAMTS13 Deficiency. American Journal of Kidney Diseases, 2014, 64, 317-318.	1.9	14
111	Drug-Induced Thrombocytopenia: An Updated Systematic Review. Annals of Internal Medicine, 2005, 142, 474.	3.9	13
112	Is immune thrombocytopenic purpura less common among black Americans?. Blood, 2005, 105, 1368-1369.	1.4	13
113	Management of Primary Immune Thrombocytopenia, 2012: A Survey of Oklahoma Hematologists-Oncologists. American Journal of the Medical Sciences, 2014, 347, 190-194.	1.1	13
114	Reports of Drug-Induced Thrombocytopenia. Annals of Internal Medicine, 2003, 138, 239.	3.9	13
115	ADAMTS13 and TTP: the clot thickens. Blood, 2004, 103, 3997-3998.	1.4	12
116	Drug-Induced Thrombocytopenia. Drug Safety, 2007, 30, 185-186.	3.2	12
117	Support groups for patients who have recovered from thrombotic thrombocytopenic purpura. Journal of Clinical Apheresis, 2008, 23, 168-169.	1.3	12
118	Prospective Associations Among Assets and Successful Transition to Early Adulthood. American Journal of Public Health, 2015, 105, e51-e56.	2.7	12
119	Addendum to corticosteroid side effects and risk for bleeding in immune thrombocytopenic purpura: patient perspectives. European Journal of Haematology, 2009, 83, 497-498.	2.2	11
120	Determining a definite diagnosis of primary immune thrombocytopenia by medical record review. American Journal of Hematology, 2012, 87, 843-847.	4.1	11
121	Management of antithrombotic therapy in adults with immune thrombocytopenia (ITP): a survey of ITP specialists and general hematologist–oncologists. Journal of Thrombosis and Thrombolysis, 2018, 46, 24-30.	2.1	11
122	Development of thrombocytopenia is associated with improved survival in patients treated with immunotherapy. Future Science OA, 2020, 6, FSO581.	1.9	11
123	The Incidence of TTP-HUS: Racial Disparity among Patients with Severe ADAMTS13 Deficiency Blood, 2004, 104, 857-857.	1.4	11
124	Health risk aversion, health risk affinity, and socio-economic position in the USA: The demographics of multiple risk. Health, Risk and Society, 2000, 2, 295-314.	1.7	10
125	Parental Youth Assets and Sexual Activity: Differences by Race/Ethnicity. American Journal of Health Behavior, 2011, 35, 513-24.	1.4	10
126	Quantitation of coated platelet potential during collection, storage, and transfusion of apheresis platelets. Transfusion, 2011, 51, 2690-2694.	1.6	10

#	Article	IF	Citations
127	A multiple motive/multi-dimensional approach to measure smokeless tobacco dependence. Addictive Behaviors, 2014, 39, 622-629.	3.0	10
128	How to write a guideline: a proposal for a manuscript template that supports the creation of trustworthy guidelines. Blood Advances, 2021, 5, 4721-4726.	5.2	10
129	How Can We Provide the Best Care for Our Patients With Immune Thrombocytopenic Purpura?. Mayo Clinic Proceedings, 2004, 79, 456-457.	3.0	9
130	The influence of assets and environmental factors on gender differences in adolescent drug use. Journal of Adolescence, 2014, 37, 827-837.	2.4	9
131	The Predictive Influence of Youth Assets on Drinking and Driving Behaviors in Adolescence and Young Adulthood. Journal of Primary Prevention, 2016, 37, 231-245.	1.6	9
132	Long-term Kidney Outcomes in Patients With Acquired Thrombotic Thrombocytopenic Purpura. Kidney International Reports, 2017, 2, 1088-1095.	0.8	9
133	Predictors of Outcome in Patients With Fibrolamellar Carcinoma: Analysis of the National Cancer Database. Anticancer Research, 2020, 40, 847-855.	1.1	9
134	Youth Assets and Sexual Abstinence in Native American Youth. Journal of Health Care for the Poor and Underserved, 2006, 17, 775-788.	0.8	8
135	Referral of patients with thrombocytopenia from primary care clinicians to hematologists. Blood, 2009, 113, 4126-4127.	1.4	8
136	Depression in adult patients with primary immune thrombocytopenia. American Journal of Hematology, 2016, 91, E462-3.	4.1	8
137	Laboratory monitoring during pregnancy and postâ€partum hemorrhage in women with von Willebrand disease. Journal of Thrombosis and Haemostasis, 2020, 18, 604-608.	3.8	8
138	Outcomes and Prognostic Factors of Resected Salivary Gland Malignancies: Examining a Single Institution's 12-year Experience. Anticancer Research, 2017, 37, 5019-5025.	1.1	8
139	The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome Registry: a community service. Journal - Oklahoma State Medical Association, 2007, 100, 273-8.	0.4	8
140	Youth assets, aggression, and delinquency within the context of family structure. American Journal of Health Behavior, 2005, 29, 557-68.	1.4	8
141	A seasonal association of incident cases of thrombotic thrombocytopenic purpura was not observed in the Oklahoma TTPâ€HUS Registry. Transfusion, 2012, 52, 1593-1594.	1.6	7
142	Prospective Association Between Negative Life Events and Initiation of Sexual Intercourse: The Influence of Family Structure and Family Income. American Journal of Public Health, 2015, 105, 598-604.	2.7	7
143	Disparity in outcomes of melanoma adjuvant immunotherapy by demographic profile. Melanoma Management, 2020, 7, MMT43.	0.5	7
144	A youth development approach to profiling sexual abstinence. American Journal of Health Behavior, 2003, 27 Suppl 1, S80-93.	1.4	7

#	Article	IF	CITATIONS
145	Patterns of Care for Localized Breast Cancer in Oklahoma, 2003–2006. Women and Health, 2015, 55, 975-995.	1.0	6
146	Impact of gender and caregiving responsibilities on academic success in hematology. Blood Advances, 2020, 4, 755-761.	5.2	6
147	Youth gender differences in alcohol use: A prospective study of multiple youth assets and the neighborhood environment. Open Journal of Preventive Medicine, 2013, 03, 219-228.	0.3	6
148	Inpatient versus outpatient management of neutropenic fever in gynecologic oncology patients: Is risk stratification useful?. Gynecologic Oncology, 2013, 130, 411-415.	1.4	5
149	Prospective Associations between Negative Life Events and Youth Tobacco Use. American Journal of Health Behavior, 2014, 38, 942-950.	1.4	5
150	The American Society of Hematology Clinical Research Training Institute is associated with high retention in academic hematology. Blood, 2016, 128, 2881-2885.	1.4	5
151	Beyond the Effects of Comprehensive Sexuality Education: The Significant Prospective Effects of Youth Assets on Contraceptive Behaviors. Journal of Adolescent Health, 2017, 61, 678-684.	2.5	5
152	Prospective Evaluation of Multinational Association of Supportive Care in Cancer Risk Index Score for Gynecologic Oncology Patients With Febrile Neutropenia. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 138-142.	1.3	5
153	New methods facilitated the process of prioritizing questions and health outcomes in guideline development. Journal of Clinical Epidemiology, 2022, 143, 91-104.	5.0	5
154	Associations between Youth Assets and Sexual Intercourse by Household Income. American Journal of Health Promotion, 2011, 25, 301-309.	1.7	4
155	Sexual Knowledge, Attitudes, and Behaviors of Youth Living in Group Homes. Health Behavior and Policy Review, 2018, 5, 74-87.	0.4	4
156	Von Willebrand disease screening in women undergoing hysterectomy for heavy menstrual bleeding. Haemophilia, 2019, 25, e188-e191.	2.1	4
157	Development and application of health outcome descriptors facilitated decision-making in the production of practice guidelines. Journal of Clinical Epidemiology, 2021, 138, 115-127.	5.0	4
158	Predicting Risk for Relapse in Patients Who Have Recovered from Thrombotic Thrombocytopenic Purpura (TTP) Blood, 2006, 108, 91-91.	1.4	4
159	Ribosomal and Immune Transcripts Associate with Relapse in Acquired ADAMTS13-Deficient Thrombotic Thrombocytopenic Purpura. PLoS ONE, 2015, 10, e0117614.	2.5	4
160	Prevalence of neuropsychiatric symptoms and stroke in patients with hereditary thrombotic thrombocytopenic purpura. Blood, 2022, 140, 785-789.	1.4	4
161	Sexuality Education Beliefs Among Sexually Experienced Youth. American Journal of Sexuality Education, 2006, 1 , 3-23.	1.0	3
162	The association of attendance at religious services and involvement in church/religious activities and youth assets, by gender, with youth's engagement in sexual intercourse. Health Education, 2010, 110, 125-134.	0.9	3

#	Article	IF	Citations
163	An automatic 3D CT/PET segmentation framework for bone marrow proliferation assessment., 2016, 2016, 4126-4130.		3
164	Prospective Associations Among Youth Religiosity and Religious Denomination and Youth Contraception Use. Journal of Religion and Health, 2020, 59, 555-569.	1.7	3
165	Thrombotic Thrombocytopenic Purpura (TTP) and Systemic Lupus Erythematosus (SLE): Distinct but Potentially Overlapping Syndromes Blood, 2004, 104, 858-858.	1.4	3
166	Evidence for a Pathophysiological Role of Anti-ADAMTS13 Antibodies Despite the Presence of Normal ADAMTS13 Activity and Presumption of an Epitope Spreading over Time in Recurrent Thrombotic Thrombocytopenic Purpura (TTP) Blood, 2006, 108, 1067-1067.	1.4	3
167	Neurocognitive Impairment Following Recovery from ADAMTS13-Deficient Thrombotic Thrombocytopenia Purpura (TTP) Blood, 2007, 110, 1311-1311.	1.4	3
168	The Prevalence of Immune Thrombocytopenic Purpura (ITP) Blood, 2008, 112, 1277-1277.	1.4	3
169	Youth Assets and Sexual Risk Behavior: The Importance of Assets for Youth Residing in One-Parent Households. Perspectives on Sexual and Reproductive Health, 2005, 37, 25-31.	3.3	3
170	The Prospective Association of Youth Assets With Tobacco Use in Young Adulthood. American Journal of Health Education, 2015, 46, 329-337.	0.6	2
171	Towards automatic 3D bone marrow segmentation. , 2016, , .		2
172	Demographic Factors Predict Disparities in Number of Assets Youth Possess. American Journal of Health Behavior, 2017, 41, 652-660.	1.4	2
173	Long-Term Follow-Up of 21 Patients with Thrombotic Thrombocytopenic Purpura (TTP) and Severe ADAMTS13 Deficiency: Demonstration of Persistent ADAMTS13 Deficiency and Neurocognitive Abnormalities Blood, 2004, 104, 856-856.	1.4	2
174	Long-Term Abnormalities of Patient-Reported Outcomes after Recovery from Thrombotic Thrombocytopenic Purpura (TTP) Using Health Related Quality-of-Life (QOL) Measurements Blood, 2006, 108, 458-458.	1.4	2
175	First Symptoms In Idiopathic Thrombotic Thrombocytopenic Purpura (TTP): What Are They and When Do They Occur? Blood, 2010, 116, 1427-1427.	1.4	2
176	Von Willebrand Disease Screening in Women Undergoing Hysterectomy for Heavy Menstrual Bleeding. Blood, 2017, 130, 674-674.	1.4	2
177	Longâ€ŧerm outcomes of healthâ€ŧelated quality of life following diverse thrombotic microangiopathy syndromes. American Journal of Hematology, 2016, 91, E278-9.	4.1	1
178	Response to Comment on O'Brien et al. Hormonal Contraception and Risk of Thromboembolism in Women With Diabetes. Diabetes Care 2017;40:233–238. Diabetes Care, 2017, 40, e62-e62.	8.6	1
179	A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium Journal of Clinical Oncology, 2021, 39, 5527-5527.	1.6	1
180	Thrombotic Thrombocytopenic Purpura (TTP) Patient Attitudes Regarding Depression Management: a Qualitative Study. Blood, 2014, 124, 203-203.	1.4	1

#	Article	IF	Citations
181	The impact of BMI on the response to immunotherapy in lung cancer Journal of Clinical Oncology, 2022, 40, e21003-e21003.	1.6	1
182	Tobacco Use in Adults With Mental Illness: An Overview of One State-Wide Tobacco Cessation Program. Journal of Smoking Cessation, 2019, 14, 132-137.	1.0	0
183	Self-reported positive impact of mentored clinical research training is associated with academic success in hematology. Blood Advances, 2021, 5, 2919-2924.	5.2	0
184	Minor Surgical Procedures - Survey of Hematologists To Determine Preferences Regarding Management of Hemophilia Patients Blood, 2006, 108, 4067-4067.	1.4	0
185	Prognostic significance of weight loss and nutritional markers during induction chemotherapy of newly diagnosed acute myeloid leukemia (AML) patients Journal of Clinical Oncology, 2016, 34, e21591-e21591.	1.6	0
186	Poorly differentiated malignant salivary gland tumors (MSGTs) amenable to resection and their association with higher stage, higher prevalence in males, and poor prognosis Journal of Clinical Oncology, 2016, 34, e17563-e17563.	1.6	0
187	Can DNA methylation patterns be used as predictive biomarkers for chemotherapy response in osteosarcoma?. Journal of Clinical Oncology, 2018, 36, 11525-11525.	1.6	0
188	Clinical characteristics and predictors of outcomes in patients with fibrolamellar carcinoma: An eleven-year analysis of the National Cancer Database (NCDB) Journal of Clinical Oncology, 2019, 37, 413-413.	1.6	0
189	PD-L1, brain metastases, and survival among patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors Journal of Clinical Oncology, 2020, 38, e21655-e21655.	1.6	0
190	Preferences for Accessing Patient Reported Outcomes and Health Information Among Thrombotic Thrombocytopenic Purpura Survivors. Blood, 2021, 138, 3039-3039.	1.4	0
191	Abstract P3-19-20: Are traditional indications for radiation therapy appropriate for small cell carcinoma of the breast: An NCDB outcomes analysis and treatment utilization report. Cancer Research, 2022, 82, P3-19-20-P3-19-20.	0.9	0
192	Immune Thrombocytopenic Purpura. , 0, , 206-214.		0